Board member Khosla resigns; Ramdeen appointed to Audit Committee; CEO Sapirstein gets post-termination medical benefits

GridAI Technologies Corp.

Chaitan Khosla resigned from Board effective August 16, 2024.
Timothy Ramdeen appointed to Audit Committee on August 21, 2024 to fill the vacancy.
Independent directors approved payment of CEO James Sapirstein's post-employment medical insurance premiums for six months.
Payment maintains coverage after termination of Sapirstein's employment agreement on August 2, 2024.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Chaitan Khosla

Director

GRDX · GridAI Technologies Corp.

Effective: 2024-08-16
Filed: August 22, 2024, 7:59 PM ET

On August 16, 2024, Chaitan Khosla resigned as a member of the Board of Directors (the “Board”) of Entero Therapeutics, Inc. (the “Company”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Chaitan Khosla resigned as Director at GridAI Technologies Corp..

Action: resigned
Role: Director

Exact text from the filing

On August 16, 2024, Chaitan Khosla resigned as a member of the Board of Directors (the “Board”) of Entero Therapeutics, Inc. (the “Company”), effective immediately.

View on SEC.gov

GridAI Technologies Corp. filing history →

Source: SEC EDGAR

accession 0001104659-24-092061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.